The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
< 0.100 Eu/µg
The ED50 as determined by the dose-dependent stimulation of the proliferation of IL-6-dependent murine 7TD1 cells is < 0.01 ng/ml, corresponding to a specific activity of > 1 x 108 units/mg.
Concentration information loading...
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
We recommend a quick spin followed by reconstitution in 100ul water or buffer at pH 7.0 to a concentration of 0.1mg/ml.
Interleukin BSF 2
B cell differentiation factor
B cell stimulatory factor 2
B-cell stimulatory factor 2
CTL differentiation factor
Hepatocyte stimulatory factor
Hybridoma growth factor
Hybridoma growth factor Interferon beta-2
Interferon beta 2
Interleukin 6 (interferon beta 2)
Interleukin BSF 2
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.